Measuring Infant NeuroDevelopment Study
The ReMAPP Measuring Infant NeuroDevelopment (ReMIND) Study aims to advance clinical knowledge of the effects of maternal anemia on infant neurological development and brain morphology. Nested within the ReMAPP study, up to 300 mother-infant dyads will be selected to undergo neurodevelopmental assessments. Infant brain morphology will be assessed using the low-field, portable Hyperfine MRI done at 3 months and 1 year. The Global Scale for Early Development (GSED) Short-Form (SF), GSED Long Form (LF), & Family Care Indicator (FCI) assessments will be done at the same timepoints.